Ernexa Therapeutics (ERNA) Competitors $1.95 -0.15 (-7.14%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.00 +0.05 (+2.31%) As of 07/25/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA vs. IZTC, ANL, SCLX, UNCY, ADVM, IFRX, INMB, ATNM, KRON, and RENBShould you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Invizyne Technologies (IZTC), Adlai Nortye (ANL), Scilex (SCLX), Unicycive Therapeutics (UNCY), Adverum Biotechnologies (ADVM), InflaRx (IFRX), INmune Bio (INMB), Actinium Pharmaceuticals (ATNM), Kronos Bio (KRON), and Renovaro (RENB). These companies are all part of the "pharmaceutical products" industry. Ernexa Therapeutics vs. Its Competitors Invizyne Technologies Adlai Nortye Scilex Unicycive Therapeutics Adverum Biotechnologies InflaRx INmune Bio Actinium Pharmaceuticals Kronos Bio Renovaro Invizyne Technologies (NASDAQ:IZTC) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations. Which has better earnings & valuation, IZTC or ERNA? Invizyne Technologies has higher earnings, but lower revenue than Ernexa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/AErnexa Therapeutics$580K24.74-$44.54M-$8.31-0.23 Is IZTC or ERNA more profitable? Invizyne Technologies has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Ernexa Therapeutics -7,652.75%N/A -285.71% Does the media refer more to IZTC or ERNA? In the previous week, Invizyne Technologies and Invizyne Technologies both had 1 articles in the media. Ernexa Therapeutics' average media sentiment score of 1.87 beat Invizyne Technologies' score of 1.11 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Invizyne Technologies Positive Ernexa Therapeutics Very Positive Do institutionals and insiders believe in IZTC or ERNA? 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryErnexa Therapeutics beats Invizyne Technologies on 4 of the 6 factors compared between the two stocks. Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.47M$2.50B$5.70B$9.50BDividend YieldN/A1.75%4.60%4.01%P/E Ratio-0.239.0528.1020.05Price / Sales24.74592.30429.3789.38Price / CashN/A165.2136.2258.56Price / Book3.905.168.665.87Net Income-$44.54M$30.99M$3.25B$258.55M7 Day Performance-1.52%7.74%4.22%3.73%1 Month Performance2.63%16.27%10.51%11.75%1 Year Performance-92.82%-1.88%34.40%18.03% Ernexa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAErnexa Therapeutics1.097 of 5 stars$1.95-7.1%N/A-92.8%$15.47M$580K-0.2310Positive NewsGap UpHigh Trading VolumeIZTCInvizyne TechnologiesN/A$9.25flatN/AN/A$57.83MN/A0.0029News CoverageGap UpANLAdlai Nortye1.8974 of 5 stars$1.55+2.0%$9.00+480.6%-57.6%$57.20M$5M0.00127SCLXScilex2.3836 of 5 stars$8.16-5.2%$455.00+5,479.4%-79.9%$56.67M$56.59M-0.2880News CoverageHigh Trading VolumeUNCYUnicycive Therapeutics3.0066 of 5 stars$4.51+0.1%$60.00+1,231.9%+10.7%$56.64M$680K-0.889ADVMAdverum Biotechnologies4.5236 of 5 stars$2.72+0.2%$23.80+776.6%-66.6%$56.40M$1M-0.42190News CoveragePositive NewsIFRXInflaRx2.4447 of 5 stars$0.84-2.5%$6.60+689.5%-41.3%$56.39M$180K-1.0260INMBINmune Bio2.3077 of 5 stars$2.37-0.6%$18.40+678.0%-68.0%$55.74M$10K-1.2210Positive NewsUpcoming EarningsATNMActinium Pharmaceuticals2.4484 of 5 stars$1.74+2.7%$4.00+130.5%N/A$54.13MN/A-1.2530KRONKronos BioN/A$0.88+1.5%$1.63+84.7%-34.3%$53.72M$9.85M-0.82100RENBRenovaro2.2249 of 5 stars$0.31+0.6%N/A-75.3%$53.36MN/A-0.4020 Related Companies and Tools Related Companies IZTC Alternatives ANL Alternatives SCLX Alternatives UNCY Alternatives ADVM Alternatives IFRX Alternatives INMB Alternatives ATNM Alternatives KRON Alternatives RENB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERNA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
